Effect of renal cell carcinomas on the development of type 1 T-cell responses

Clinical Cancer Research

Volumn 10, Issue 18 II, 2004, Pages

  Rayman, Patricia ^a   Wesa, Amy K ^b   Richmond, Amy L ^a   Das, Tanya ^c   Biswas, Kaushik ^a   Raval, Gira ^a   Storkus, Walter J ^b   Tannenbaum, Charles ^a   Novick, Andrew ^a   Bukowski, Ronald ^a   Finke, James ^a   Yang, James ^d   Atkins, Michael ^d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c BOSE INSTITUTE   (India)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GANGLIOSIDE; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; IONOMYCIN; PHORBOL 13 ACETATE 12 MYRISTATE; STAPHYLOCOCCUS ENTEROTOXIN B; SUPERANTIGEN;

APOPTOSIS; CELL CULTURE; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DOWN REGULATION; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; KIDNEY CARCINOMA; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

CARCINOMA, RENAL CELL; CD4 LYMPHOCYTE COUNT; CYTOKINES; GANGLIOSIDES; HUMANS; KIDNEY NEOPLASMS; T-LYMPHOCYTES; TH1 CELLS; TH2 CELLS;

EID: 4644224963     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-050011     Document Type: Conference Paper

References (45)

1. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003;421:852-6.
2. Gajewski TF, Fallarino F. Rational development of tumour antigen-specific immunization in melanoma. Ther Immunol 1995;2:211-25.
3. Matsui S, Ahlers JD, Vortmeyer AO, et al. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J Immunol 1999;163:184-93.
4. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998;187:693-702.
5. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-93.
6. Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 1997;15:297-322.
7. Levings MK, Bacchetta R, Schulz U, Roncarolo MG. The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 2002;129:263-76.
8. Chatenoud L, Salomon B, Bluestone JA. Suppressor T cells-they're back and critical for regulation of autoimmunity! Immunol Rev 2001;182:149-63.
9. Angevin E, Kremer F, Gaudin C, Hercend T, Triebel F. Analysis of T-cell immune response in renal cell carcinoma: polarization to type I-like differentiation pattern, clonal T-cell expansion and tumor-specific cytotoxicity. Int J Cancer 1997;72:431-40.
10. Schoof DD, Terashima Y, Peoples GE, et al. CD4+ T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells. Cell Immunol 1993;150:114-23.
11. Goldman M, Druet P. The TH1/TH2 concept and its relevance to renal disorders and transplantation immunity. Nephrol Dial Transplant 1995;10:1282-4.
12. Elsasser-Beile U, Kolble N, Grussenmeyer T, et al. Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas. Tumour Biol 1998;19:470-6.
13. Fridman WH, Tartour E. Macrophage- and lymphocyte-produced Th1 and Th2 cytokines in the tumour microenvironment. Res Immunol 1998;149:651-3.
14. Wang Q, Redovan C, Tubbs R, et al. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int J Cancer 1995;61:780-5.
15. Tatsumi T, Kierstead LS, Ranieri E, et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 2002;196:619-28.
16. Tatsumi T, Kierstead LS, Ranieri E, et al. MAGE-6 encodes HLA-DRbeta1 *0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res 2003;9:947-54.
17. Tatsumi T, Herrem CJ, Olson WC, et al. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 2003;63:4481-9.
18. Tatsumi T, Wesa A, Finke J, Bukowski R, Storkus W. CD4 T cell-mediated immunity to cancer. In: J. Finke, R. Bukowski editors. Cancer immunotherapy at the crossroads: how tumors evade immunity and what can be done. Totowa, NJ: Humana Press 2004. pp. 67-86.
19. McKallip R, Li R, Ladisch S. Tumor gangliosides inhibit the tumor-specific immune response. J Immunol 1999;163:3718-26.
20. Thornton MV, Kudo D, Rayman P, et al. Degradation of NF-kappaB in T cells by gangliosides expressed on renal cell carcinomas. J Immunol 2004;172:3480-90.
21. Hoon DS, Okun E, Neuwirth H, Morton DL, Irie RF. Aberrant expression of gangliosides in human renal cell carcinomas. J Urol 1993;150:2013-8.
22. Raval GN, Parekh LJ, Patel MM, et al. Role of sialic acid and alkaline DNase in breast cancer. Int J Biol Markers 1997;12:61-7.
23. Finke JH, Rayman P, George R, et al. Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: role of nuclear factor-kappaB suppression. Clin Cancer Res 2001;7:940s-6s.
24. Edwards MJ, Anderson JA, Angel JR, Harty JI. Spontaneous regression of primary and metastatic renal cell carcinoma. J Urol 1996;155:1385.
25. Kliem V, Kolditz M, Behrend M, et al. Risk of renal cell carcinoma after kidney transplantation. Clin Transplant 1997;11:255-8.
26. Kunisch-Hoppe M, Hoppe M, Bohle RM, et al. Metastatic RCC arising in a transplant kidney. Eur Radiol 1998;8:1441-3.
27. Finke JH, Rayman P, Hart L, et al. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation. J Immunother Emphasis Tumor Immunol 1994;15:91-104.
28. Finke JH, Rayman P, Alexander J, et al. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res 1990;50:2363-70.
29. Belldegrun A, Kasid A, Uppenkamp M, Rosenberg SA. Lymphokine mRNA profile and functional analysis of a human CD4+ clone with unique antitumor specificity isolated from renal cell carcinoma ascitic fluid. Cancer Immunol Immunother 1990;31:1-10.
30. Schendel DJ, Gansbacher B, Oberneder R, et al. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 1993;151:4209-20.
31. Puisieux I, Bain C, Merrouche Y, et al. Restriction of the T-cell repertoire in tumor-infiltrating lymphocytes from nine patients with renal-cell carcinoma. Relevance of the CDR3 length analysis for the identification of in situ clonal T-cell expansions. Int J Cancer 1996;66:201-8.
32. Onishi T, Ohishi Y, Goto H, Tomita M, Abe K. An assessment of the immunological status of patients with renal cell carcinoma based on the relative abundance of T-helper 1- and -2 cytokine-producing CD4+ cells in peripheral blood. BJU Int 2001;87:755-9.
33. Nagai H, Hara I, Horikawa T, Oka M, Kamidono S, Ichihashi M. Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration. J Invest Dermatol 2000;115:1059-64.
34. Seo N, Hayakawa S, Takigawa M, Tokura Y. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology 2001;103:449-57.
35. Nebl T, Pestonjamasp KN, Leszyk JD, Crowley JL, Oh SW, Luna EJ. Proteomic analysis of a detergent-resistant membrane skeleton from neutrophil plasma membranes. J Biol Chem 2002;277:43399-409.
36. Ladisch S, Gillard B, Wong C, Ulsh L. Shedding and immunoregulatory activity of YAC-I lymphoma cell gangliosides. Cancer Res 1983;43:3808-13.
37. Black PH. Shedding from the cell surface of normal and cancer cells. Adv Cancer Res 1980;32:75-199.
38. Ritter G, Livingston PO. Ganglioside antigens expressed by human cancer cells. Semin Cancer Biol 1991;2:401-9.
39. Li R, Villacreses N, Ladisch S. Human tumor gangliosides inhibit murine immune responses in vivo. Cancer Res 1995;55:211-4.
40. Ladisch S, Li R, Olson E. Ceramide structure predicts tumor ganglioside immunosuppressive activity. Proc Natl Acad Sci USA 1994;91:1974-8.
41. Irani DN, Lin KI, Griffin DE. Brain-derived gangliosides regulate the cytokine production and proliferation of activated T cells. J Immunol 1996;157:4333-40.
42. Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK, Reisfeld RA. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 1984;44:5914-20.
43. Valentino L, Moss T, Olson E, Wang HJ, Elashoff R, Ladisch S. Shed tumor gangliosides and progression of human neuroblastoma. Blood 1990;75:1564-7.
44. Uzzo RG, Rayman P, Kolenko V, et al. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res 1999;5:1219-29.
45. Saito T, Dworacki G, Gooding W, Lotze MT, Whiteside TL. Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. Clin Cancer Res 2000;6:1351-64.